Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Sangart commences MP4CO Phase 1b study in sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease.

12 Jan 2012

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

19 Dec 2011

Mandatory screening helps identify more athletes with SCT

In response to a lawsuit after a college football player died from complications due to sickle cell trait (SCT) during a workout, the NCAA implemented mandatory SCT screening of all Division I student-athletes.

14 Dec 2011

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Research examines novel treatment techniques for hemophilia B, VTE

Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Re-treatment with rituximab may benefit patients with LTB follicular lymphoma

Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been watched for signs or symptoms of disease progression and then treated with a combination of rituximab and chemotherapy or rituximab alone for select cases. Recent trials have suggested a role for treatment of asymptomatic patients with single-agent rituximab followed by additional periodic dosing, called "maintenance therapy."

12 Dec 2011

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Study may help personalize pain medication management for sickle cell disease patients

A study that may help personalize pain medication management for sickle cell disease patients is underway at Georgia Health Sciences University.

9 Dec 2011

New gene editing technique can heal sickle cell patients with their own cells

Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.

8 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis

ADVENTRX Pharmaceuticals, Inc. announced today that it met with the U.S. Food and Drug Administration (FDA) to review development plans for ANX-188 (purified poloxamer 188), the Company's first-in-class treatment for sickle cell patients experiencing vaso-occlusive crisis.

1 Dec 2011

Anemia, high blood pressure linked to risk of silent strokes in children with SCD

A team of researchers from the Johns Hopkins Children's Center, Vanderbilt University and elsewhere have demonstrated that high blood pressure and anemia together put children with sickle cell disease (SCD) at serious danger for symptomless or so-called "silent" strokes, although either condition alone also signaled high risk.

30 Nov 2011

CINJ experts available to comment on blood donations

Every two seconds, someone in the United States is in need of blood. According to the American Red Cross, more than 38,000 blood donations are needed each day. With just one donation of a pint of blood, up to three lives can be saved. In New Jersey, according to the state Department of Health and Senior Services, fewer than four percent of eligible residents donate regularly, resulting in the need for critical blood donations.

18 Nov 2011

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).

17 Nov 2011

New blood spot analysis method can diagnose range of clinical conditions

Scientists have developed a rapid method that can be used to simultaneously screen patients for a range of genetic and acquired clinical conditions from a single dried blood spot.

17 Nov 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

Public health officials should address needs of people with blood disorders

Public health should focus not only on reducing the burden of common diseases but also address the needs of people with blood disorders , experts say in a supplement to December's American Journal of Preventive Medicine.

16 Nov 2011

Cortex third quarter net loss increases to $1,175,000

Cortex Pharmaceuticals, Inc. reported a net loss of approximately $1,175,000, or $0.01 per share, for the quarter ended September 30, 2011, compared with a net loss of approximately $528,000, or $0.01 per share, for the corresponding prior year quarter.

14 Nov 2011

ADVENTRX prices underwritten public offering of common stock

ADVENTRX Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 21,250,000 shares of its common stock and warrants exercisable for up to 10,625,000 additional shares at $0.80 per fixed combination of shares and warrants for gross proceeds of approximately $17 million.

11 Nov 2011

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Sangart commences MP4CO Phase 1b study in sickle cell disease

Phase I clinical study of Selexys SelG1 for sickle cell disease completed

Mandatory screening helps identify more athletes with SCT

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research examines novel treatment techniques for hemophilia B, VTE

Re-treatment with rituximab may benefit patients with LTB follicular lymphoma

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Study may help personalize pain medication management for sickle cell disease patients

New gene editing technique can heal sickle cell patients with their own cells

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

ADVENTRX, FDA discuss ANX-188 development plans for treatment of sickle cell crisis

Anemia, high blood pressure linked to risk of silent strokes in children with SCD

CINJ experts available to comment on blood donations

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

New blood spot analysis method can diagnose range of clinical conditions

Researchers to begin drug development projects for rare and neglected diseases

Public health officials should address needs of people with blood disorders

Cortex third quarter net loss increases to $1,175,000

ADVENTRX prices underwritten public offering of common stock

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Sickle Cell Disease News and Research

Latest Sickle Cell Disease News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in